A Study of LY2951742 (Galcanezumab) in Japanese Participants With Episodic Migraine
A Study of LY2951742 (Galcanezumab) in Japanese Participants With Episodic Migraine
The main purpose of this study is to determine the efficacy of the study drug Galcanezumab in
 Japanese participants with episodic migraine.
Inclusion Criteria:

 -  Have a diagnosis of migraine as defined by International Headache Society (IHS)
 International Classification of Headache Disorders (ICHD)-3 beta guidelines (1.1 or
 1.2) (ICHD-3 2013), with a history of migraine headaches of at least 1 year prior to
 screening, and migraine onset prior to age 50.

 Exclusion Criteria:

 -  Are currently enrolled in or have participated within the last 30 days or within 5
 half-lives (whichever is longer) in a clinical trial involving an investigational
 product.

 -  Current use or prior exposure to Galcanezumab or other antibodies to CGRP or its
 receptor.

 -  Known hypersensitivity to multiple drugs, monoclonal antibodies or other therapeutic
 proteins, or to Galcanezumab and the excipients in the investigational product.

 -  History of persistent daily headache, cluster headache or migraine subtypes including
 hemiplegic (sporadic or familial) migraine, ophthalmoplegic migraine, and migraine
 with brainstem aura (basilar-type migraine) defined by IHS ICHD-3 beta.